Involvement of B Cells in the Development of Systemic Sclerosis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Aug 15

PMID 35967355

Authors

Ayumi Yoshizaki

Takemichi Fukasawa

Satoshi Ebata

Asako Yoshizaki-Ogawa

Shinichi Sato

Affiliations

Soon will be listed here.

Abstract

Systemic sclerosis (SSc) is a rare intractable systemic disease that causes fibrosis and vasculopathy against a background of autoimmune abnormalities. Although the etiology is not yet fully understood, the type of autoantibodies detected in SSc is closely associated with disease severity and prognosis, supporting that those autoimmune abnormalities play an important role in the pathogenesis of SSc. Although the direct pathogenicity of autoantibodies found in SSc is unknown, many previous studies have shown that B cells are involved in the development of SSc through a variety of functions. Furthermore, a number of clinical studies have been conducted in which B-cell depletion therapy has been tried for SSc, and many of these studies have found B-cell depletion therapy to be effective for SSc. However, the involvement of B cells in pathogenesis is complex, as they not only promote inflammation but also play an inhibitory role. This article outlines the role of B cells in the development of SSc, including the latest research.

Citing Articles

The B-cells paradigm in systemic sclerosis: an update on pathophysiology and B-cell-targeted therapies.

Scaletti C, Pratesi S, Bellando Randone S, Di Pietro L, Campochiaro C, Annunziato F Clin Exp Immunol. 2024; 219(1).

PMID: 39498828 PMC: 11754866. DOI: 10.1093/cei/uxae098.

Diversity and Epitope Spreading of Anti-RNA Polymerase III Antibodies in Systemic Sclerosis: A Potential Biomarker for Skin and Lung Involvement.

Kotani H, Matsuda K, Yamaguchi K, Ono C, Kogo E, Ogawa K Arthritis Rheumatol. 2024; 77(1):67-79.

PMID: 39219033 PMC: 11684998. DOI: 10.1002/art.42975.

Breg-Mediated Immunoregulation in the Skin.

Zheremyan E, Ustiugova A, Karamushka N, Uvarova A, Stasevich E, Bogolyubova A Int J Mol Sci. 2024; 25(1).

PMID: 38203754 PMC: 10778726. DOI: 10.3390/ijms25010583.

Identification of lncRNA-miRNA-mRNA networks in circulating exosomes as potential biomarkers for systemic sclerosis.

Sun X, Ding T, Wang B, Chang Z, Fei H, Geng L Front Med (Lausanne). 2023; 10:1111812.

PMID: 36873898 PMC: 9977830. DOI: 10.3389/fmed.2023.1111812.

Increased expression of the ectoenzyme CD38 in peripheral blood plasmablasts and plasma cells of patients with systemic sclerosis.

Agarbati S, Benfaremo D, Viola N, Paolini C, Svegliati Baroni S, Funaro A Front Immunol. 2023; 13:1072462.

PMID: 36618427 PMC: 9811259. DOI: 10.3389/fimmu.2022.1072462.

References

Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P . Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014; 371(19):1771-80. DOI: 10.1056/NEJMoa1404231. View

Mauri C, Menon M . Human regulatory B cells in health and disease: therapeutic potential. J Clin Invest. 2017; 127(3):772-779. PMC: 5330739. DOI: 10.1172/JCI85113. View

Sato S, Fujimoto M, Hasegawa M, Takehara K, Tedder T . Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol. 2004; 41(12):1123-33. DOI: 10.1016/j.molimm.2004.06.025. View

Senecal J, Hoa S, Yang R, Koenig M . Pathogenic roles of autoantibodies in systemic sclerosis: Current understandings in pathogenesis. J Scleroderma Relat Disord. 2022; 5(2):103-129. PMC: 8922609. DOI: 10.1177/2397198319870667. View

Smith V, Van Praet J, Vandooren B, Van der Cruyssen B, Naeyaert J, Decuman S . Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2008; 69(1):193-7. DOI: 10.1136/ard.2008.095463. View

Fukasawa T, Yoshizaki A, Ebata S, Nakamura K, Saigusa R, Miura S . Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis. Arthritis Rheumatol. 2017; 69(9):1879-1890. DOI: 10.1002/art.40164. View

Cragg M, Morgan S, Chan H, Morgan B, Filatov A, Johnson P . Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2002; 101(3):1045-52. DOI: 10.1182/blood-2002-06-1761. View

Yoshizaki A, Yanaba K, Ogawa A, Asano Y, Kadono T, Sato S . Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum. 2011; 63(11):3575-85. DOI: 10.1002/art.30539. View

Carter R, Wang Y, Brooks S . Role of CD19 signal transduction in B cell biology. Immunol Res. 2002; 26(1-3):45-54. DOI: 10.1385/IR:26:1-3:045. View

10.

Basu B, Angeletti A, Islam B, Ghiggeri G . New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?. Front Immunol. 2022; 13:805697. PMC: 8873567. DOI: 10.3389/fimmu.2022.805697. View

11.

OReilly S, Hugle T, van Laar J . T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford). 2012; 51(9):1540-9. DOI: 10.1093/rheumatology/kes090. View

12.

Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K . Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther. 2016; 18(1):131. PMC: 4895815. DOI: 10.1186/s13075-016-1021-2. View

13.

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

14.

Zhang X, Deriaud E, Jiao X, Braun D, Leclerc C, Lo-Man R . Type I interferons protect neonates from acute inflammation through interleukin 10-producing B cells. J Exp Med. 2007; 204(5):1107-18. PMC: 2118587. DOI: 10.1084/jem.20062013. View

15.

Catapano F, Chaudhry A, Jones R, Smith K, Jayne D . Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010; 25(11):3586-92. DOI: 10.1093/ndt/gfq256. View

16.

Numajiri H, Kuzumi A, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y . B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis. Arthritis Rheumatol. 2021; 73(11):2086-2095. DOI: 10.1002/art.41798. View

17.

Ebata S, Yoshizaki A, Fukasawa T, Miura S, Takahashi T, Sumida H . Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. J Dermatol. 2019; 46(11):1006-1013. DOI: 10.1111/1346-8138.15079. View

18.

Cariappa A, Boboila C, Moran S, Liu H, Shi H, Pillai S . The recirculating B cell pool contains two functionally distinct, long-lived, posttransitional, follicular B cell populations. J Immunol. 2007; 179(4):2270-81. DOI: 10.4049/jimmunol.179.4.2270. View

19.

Yoshizaki A . B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets. J Dermatol. 2016; 43(1):39-45. DOI: 10.1111/1346-8138.13184. View

20.

Xing X, Yang J, Yang X, Wei Y, Zhu L, Gao D . IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway. PLoS One. 2013; 8(12):e85032. PMC: 3871633. DOI: 10.1371/journal.pone.0085032. View